Home
SONN
SONN News

Latest Sonnet BioTherapeutics Holdings Inc. (SONN) News on July 12, 2025

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

GlobeNewswire

2 months ago

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Sonnet Releases Virtual Investor "What This Means" Segment

GlobeNewswire

3 months ago

Sonnet Releases Virtual Investor "What This Means" Segment

GlobeNewswire

3 months ago

Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Sonnet Announces Release of Corporate Update Video

GlobeNewswire

3 months ago

Sonnet Announces Release of Corporate Update Video

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

GlobeNewswire

3 months ago

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

GlobeNewswire

4 months ago

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

GlobeNewswire

4 months ago

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

GlobeNewswire

4 months ago

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

GlobeNewswire

5 months ago

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

GlobeNewswire

5 months ago

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

GlobeNewswire

5 months ago

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

GlobeNewswire

5 months ago

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

GlobeNewswire

5 months ago

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

GlobeNewswire

5 months ago

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

GlobeNewswire

6 months ago

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

GlobeNewswire

6 months ago

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

GlobeNewswire

7 months ago

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire

7 months ago

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

GlobeNewswire

7 months ago

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

GlobeNewswire

7 months ago

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

GlobeNewswire

7 months ago

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

GlobeNewswire

8 months ago

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire

8 months ago

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

GlobeNewswire

8 months ago

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

GlobeNewswire

9 months ago

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Sonnet BioTherapeutics’ Strategic Deal to Develop DPN Treatment

TipRanks

9 months ago

Sonnet BioTherapeutics’ Strategic Deal to Develop DPN Treatment

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

GlobeNewswire

9 months ago

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

GlobeNewswire

9 months ago

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

GlobeNewswire

9 months ago

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

GlobeNewswire

10 months ago

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

GlobeNewswire

10 months ago

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

GlobeNewswire

10 months ago

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

GlobeNewswire

a year ago

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study

GlobeNewswire

a year ago

Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study

Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds

GlobeNewswire

a year ago

Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds

Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain

GlobeNewswire

a year ago

Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting

GlobeNewswire

a year ago

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting

Sonnet BioTherapeutics Announces Review of Strategic Alternatives

ACCESSWIRE

a year ago

Sonnet BioTherapeutics Announces Review of Strategic Alternatives

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

ACCESSWIRE

a year ago

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update

ACCESSWIRE

a year ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

ACCESSWIRE

a year ago

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

Newsfile

a year ago

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

ACCESSWIRE

a year ago

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective

ACCESSWIRE

a year ago

Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

ACCESSWIRE

a year ago

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

Sonnet BioTherapeutics Holdings First Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

a year ago

Sonnet BioTherapeutics Holdings First Quarter 2024 Earnings: Beats Expectations

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

ACCESSWIRE

a year ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

David Perry Bought 8.6% More Shares In Better Therapeutics

Simply Wall St.

a year ago

David Perry Bought 8.6% More Shares In Better Therapeutics

Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone

Business Wire

a year ago

Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone

EPOW’s CEO Purchased 245,000 Shares of the Company’s Ordinary Shares

GlobeNewswire

2 years ago

EPOW’s CEO Purchased 245,000 Shares of the Company’s Ordinary Shares

IHT DECLARES 54TH CONSECUTIVE ANNUAL DIVIDEND AS REVENUES CONTINUE TO CLIMB WITH RECORD DECEMBER

GlobeNewswire

2 years ago

IHT DECLARES 54TH CONSECUTIVE ANNUAL DIVIDEND AS REVENUES CONTINUE TO CLIMB WITH RECORD DECEMBER

Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States

Business Wire

2 years ago

Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States

Better Therapeutics Insiders Added US$6.57m Of Stock To Their Holdings

Simply Wall St.

2 years ago

Better Therapeutics Insiders Added US$6.57m Of Stock To Their Holdings

Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease

Business Wire

2 years ago

Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease

InnSuites Hospitality Trust Chairman James Wirth Acquires 1,500 Shares

GuruFocus.com

2 years ago

InnSuites Hospitality Trust Chairman James Wirth Acquires 1,500 Shares

Sunrise New Energy Receives Approval for Metal Sulfide-Doped Hard Carbon Composite Material Patent, Further Advancing Sodium Battery Material Frontier Technology

GlobeNewswire

2 years ago

Sunrise New Energy Receives Approval for Metal Sulfide-Doped Hard Carbon Composite Material Patent, Further Advancing Sodium Battery Material Frontier Technology

VS Media Announces Receipt of Nasdaq Minimum Bid Price Notification

GlobeNewswire

2 years ago

VS Media Announces Receipt of Nasdaq Minimum Bid Price Notification

Sunrise New Energy Full Year 2022 Earnings: US$0.98 loss per share (vs US$0.35 loss in FY 2021)

Simply Wall St.

2 years ago

Sunrise New Energy Full Year 2022 Earnings: US$0.98 loss per share (vs US$0.35 loss in FY 2021)

Sunrise New Energy Announces Breakthrough Achievement in Sodium-ion Battery Hard Carbon Composite Material with Approval of Invention Patent by National Intellectual Property Office

GlobeNewswire

2 years ago

Sunrise New Energy Announces Breakthrough Achievement in Sodium-ion Battery Hard Carbon Composite Material with Approval of Invention Patent by National Intellectual Property Office

Chairman James Wirth Acquires 2,000 Shares of InnSuites Hospitality Trust (IHT)

GuruFocus.com

2 years ago

Chairman James Wirth Acquires 2,000 Shares of InnSuites Hospitality Trust (IHT)

Sunrise New Energy Secures Highly Regarded Japanese Patent for Invention of Lithium-Ion Battery Anode Material Preparation Method

GlobeNewswire

2 years ago

Sunrise New Energy Secures Highly Regarded Japanese Patent for Invention of Lithium-Ion Battery Anode Material Preparation Method

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

ACCESSWIRE

2 years ago

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

EPOW Lead in Establishing National Battery Industry Standard Policy, Highlighting Its Position as a Benchmark in Technological Innovation, Product Quality and Management Efficiency in the Industry

GlobeNewswire

2 years ago

EPOW Lead in Establishing National Battery Industry Standard Policy, Highlighting Its Position as a Benchmark in Technological Innovation, Product Quality and Management Efficiency in the Industry

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

ACCESSWIRE

2 years ago

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

Thomson Reuters StreetEvents

2 years ago

Q3 2023 Torrid Holdings Inc Earnings Call

IHT THIRD FISCAL QUARTER REVENUES INCREASE 7%

GlobeNewswire

2 years ago

IHT THIRD FISCAL QUARTER REVENUES INCREASE 7%

Insider Buying: Chairman James Wirth Acquires Shares of InnSuites Hospitality Trust (IHT)

GuruFocus.com

2 years ago

Insider Buying: Chairman James Wirth Acquires Shares of InnSuites Hospitality Trust (IHT)

20 Countries with the Highest Teenage Pregnancy Rates

Insider Monkey

2 years ago

20 Countries with the Highest Teenage Pregnancy Rates

PAVmed Inc. (NASDAQ:PAVM) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

PAVmed Inc. (NASDAQ:PAVM) Q3 2023 Earnings Call Transcript

Share on Social Networks: